There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Perspective Therapeutics (CATX – Research ...

San Rafael, CA-based BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for life-threatening severe medical conditions, mainly for children. BMRN boasts a ...

In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), ...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ ...

BioMarin Pharmaceutical Stock Down 0.6 % Shares of NASDAQ:BMRN opened at $71.53 on Wednesday. The firm has a 50 day simple moving average of $66.83 and a 200 day simple moving average of $67.78 ...

BioMarin Pharmaceutical Inc. has a one year low of $60.63 and a one year high of $94.85. The company has a 50-day simple moving average of $66.68 and a two-hundred day simple moving average of $67.87.

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc.

We recently published a list of Paul Singer’s Latest Portfolio: Top 10 Stock Picks. In this article, we are going to take a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...